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Sixty-two patients underwent cardiac transplantation at
the University of Arizona from March 1979 to March
1985.Thirteen patients (11men and 2 women) wereover
50 years of age at the time of transplantation and 49
were under the age of 50. The mean age (± SEM) of
the patients over 50 was 53 ± 1 years. Eight of these
patients were treated with conventional immunosup-
pressive therapy (azathioprine, prednisone and rabbit
antithymocyte globulin) and five, beginning in January
1983, were treated with cyclosporine, prednisone and
rabbit antithymocyte globulin.
Early mortality (0 to 90 days) was 16% in the group
over 50 versus 18% for those under 50. The late mor-
tality (> 90 days) was36 and 33%, respectively. In both
groups, rejection and infectionwere the principal causes
Over the past two decades, the results of cardiac transplan-
tation have steadily improved. As the procedure was de-
veloped and centers were established to perform the pro-
cedure, rigid criteria for the selection of potential recipients
were adopted in an effort to achieve the best results possible.
Recently, these criteria have been modified to include a
group of patients who were otherwise eligible but were over
the age of 50 years. To determine the results of cardiac
transplantation in this older age group, we reviewed our
series of patients for a 6 year period, focusing specifically
on those over 50 years of age.
Methods
Patients. From March 1979 to March 1985, 323 patients
were referred for possible cardiac transplantation at the Uni-
versity of Arizona (Table 1). The hospital records of all
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of death. The incidence of infection was 1.9 ± 0.5 ep-
isodes per patient in those patients over 50 and 1.9 ±
0.4 in those under 50. The incidenceof rejection was 1.3
episodes per patient-year in patients over 50 and 1.7
episodes per patient-year in those under 50. Actuarial
survival at 1 year was 72 ± 14% in the group over 50
and 66 ± 7% in the group under 50 years of age.
These data indicate that the results of cardiac trans-
plantation for patients over 50 do not differ significantly
from those for patients under 50. Therefore, it is con-
cluded that a rigidly defined age criterion for cardiac
transplant recipients is not acceptable. Each potential
recipient must be evaluated in terms of individual risk
and benefit from the procedure.
(J Am Colt CardioI1986;8:285-8)
patients accepted for transplantation and those having car-
diac transplantation were retrospectively reviewed.
Each candidate was carefully evaluated by complete his-
tory and physical examination, review of all referring in-
formation, radiologic and hemodynamic data, multisystem
laboratory tests and immunologic studies. Psychologic and
social evaluations were also performed. The decision to
accept or refuse a candidate was made on an individual basis
using standard guidelines other than age. All patients were
in New York Heart Association functional class IV and had
no secondary organ system disease that would otherwise
limit survival. Ninety-three patients were accepted after
evaluation and 62 transplantations were performed in 61
patients.
From March 1979 through December 1983, 32 patients
were treated with conventional immunosuppressive therapy:
azathioprine, prednisone and rabbit antithymocyte globulin
(1). Eight of these patients were over 50 years of age. After
January 1983, cyclosporine became the main immunosup-
pressive agent. Five patients over 50 and 25 patients under
50 were managed on a protocol of cyclosporine, low-dose
prednisone and rabbit antithymocyte globulin. Details of
each protocol have been published previously (2).
Surgical procedures. The operative technique has been
previously reported in detail (3). Rejection episodes were
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Table 2. Primary Cardiac Disease in 62
Patients Undergoing Transplantation
60
> 50
9 (69%)* .
3 (23%)
1(8%)
13
• Over 50 Years
• Under 50 Years
40
Age (yr) ofPatients
15 (31%)*
17 (35%)
8 (16%)
2 (4%)
2 (4%)
2 (4%)
2 (4%)
1(2%)
49
< 50
20
Cause
*p < 0.05.
Ischemic
Idiopathic
Viral
Valvular
Postpartum
Alcohol
Congenital
Chronic rejection
Total
Figure 1. Actuarial survival of 24 transplant patients (9 patients
> 50 and 15 patients < 50 years old) with ischemic heart disease
as the primary cause of cardiomyopathy. One year survival was
65 ± 17% for those patients over 50 years and 64 ± 13% for
those under 50 years.
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these 62 patients (Table 2). Ischemic heart disease was the
principal cause of end stage cardiac disease (9 [69%] of 13
patients) in the group over 50 years. This differs significantly
from the younger group of patients in whom ischemic heart
disease accounted for less than a third (15 [31%] of 49) of
primary cardiac diseases (p < 0.05). Patients over 50 years
old requiring cardiac transplantation after ischemic heart
disease had a mean age of 53 ± 0.5 years, which differs
significantly from that in the younger group having ischemic
cardiomyopathy (44 ± 1 years, p < 0.05). The actuarial
survival curves of these patients presenting with ischemic
disease were identical in both groups (Fig. 1).
All patients were in functional class IV and receiving
maximal medical management before transplantation. Twelve
patients (12 [24%] of 49) under 50 years of age required
in-hospital care while awaiting transplantation and seven
were receiving inotropic therapy. None of the patients in
the older group were hospitalized in the immediate trans-
plantation period.
Results
Two hundred six patients under 50 years of age were
referred for transplantation to the University of Arizona. Of
these, 72 (35%) were accepted and 49 (24%) underwent
transplantation. One hundred seventeen patients over age
50 were referred: 21 (18%) were accepted and 13 (11%)
underwent transplantation (Table 1).
Eleven men and two women were over 50 years old at
the time of transplantation. Their mean age was 53 ± 1
years (range 50 to 57). Forty-two men and seven women
were less than 50 years old (mean 36 ± 1, range 13-49).
Clinical features. Ischemic, idiopathic and viral car-
diomyopathy form the main groups of cardiac disease in
diagnosed by routine endomyocardial biopsy and treated
with pulse methylprednisolone therapy or rabbit antithy-
mocyte globulin, or both (4,5). Infections were diagnosed
and treated as rapidly as possible. Pulmonary lesions were
identified by transtracheal aspirate or transthoracic needle
aspiration if necessary (6).
Statistics. The Student t test was used to determine the
differences between groups. The chi-square test was used
to assess the significance of differences in event frequency
between groups. Significance was determined at a proba-
bility less than 0.05. The survival is expressed in actuarial
terms. Values are expressed in linearized incidence.
Table 1. Patients Referred for Cardiac Transplantation, March
1979 to March 1985
Age (yr) of
Patients
Patients < 50 > 50 Total
Accepted for transplantation
Underwent transplantation 49 13 62
Refused transplantation 4 I 5
Awaiting transplantation 4 4 8
Died while awaiting donor 15 3 18
Subtotal 72 21 93
Rejected for transplantation
Advanced age 0 40 40
Diabetes 5 3 8
Medical contraindication 12 14 26
Other medical therapy offered 9 I 10
Other surgical therapy offered 5 0 5
Others 21 2 23
Subtotal 52 60 112
Miscellaneous patients
Referred toother centers for 18 5 23
transplantation orevaluation
Died before complete evaluation 28 II 39
Undecided, before evaluation 9 5 14
Never presented, no follow-up 27 15 42
Subtotal 82 36 118
Total 206 117 323
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Figure 2. Actuarial survival of 62 transplant patients. One year
survival was 66 ± 7% for those patients under 50 and 72 ± 14%
for those over 50 years old.
< 50 (n = 49) > 50 (n = 13)
Early mortalit y
Preoperative 1 (2%) 1 (8%)
oto 3 month s 8 (16%) 1 (8%)
Total 9 (18%) 2 (16%)
Late mortality
Greater than 3 months 13 (33%) of 40 4 (36%) of II
Table 3. Mortality of 62 Patients Undergoing Transplantation
Age (yr) of Patients
Tab le 4. Causes of Death in 62 Patients
Age (yr) of Patients
Mortality . The early mortality (0 to 90 days) was 18%
for the group under 50 years of age and 16% for the older
patients . The late mortality (> 90 day s) was 33 and 36%,
respectively (Table 3).
The causes of early and late death are summarized in
Table 4. In both groups, rejection and infection were the
principal causes of death. There was no difference in the
incidence of these problems between the two groups.
Infection. The incidence of infection was 1.9 ± 0.4
episodes per patient or 1.4 episodes per patient-year in the
group under 50 and 1.9 ± 0 .5 episodes per patient or 1.I
episode s per patient-year for those over 50.
Rejection. The incidence of rejection in patients under
50 years was 2.0 ± 0 .2 epi sode s per patient or 1.7 episodes
per patient-year. In patients over 50 years old it was 2.2 ±
0.5 episodes per patient or 1.3 ep isodes per patient-year.
Survival. The mean survival was 17 ± 2 months for
patients under and 20 ± 4 months for patients over 50 years
of age . The actuarial survival at 1 year was 66 ± 7% for
the group under 50 and 72 ± 14% for the group over 50
(Fig . 2).
Early death (0 to 90 days)
Acute rejection
Infection
Donor organ failure
Multisystem failure
Arrhythm ia
Total
Late death (> 90 days)
Infecti on
Chronic rejection
Acute rejection
Arrhythmia
Lymphoma
Suicid e
Total
< 50 (n = 49)
4 (8%)
2 (4%)
1 (2%)
1 (2%)
1 (2%)
9 (18%)
5 (13%)
3 (7 .5%)
2 (5%)
) (2. 5%)
) (2.5%)
1 (2 .5%)
13 (33% ) of 40
> 50 (n = 13)
1 (8%)
1 (8%)
2 (16%)
1 (9%)
2 (18%)
1(9%)
4 (36%) of II
Discussion
Because of the high mortality rate associated with cardiac
transplantation in the early day s of the procedure, strict
criteria for recipient selection were establi shed to achieve
the best results possible. Those criteria, combined with the
continued gain in knowledge and accumulated clinical ex-
perience , have permitted the establishment of cardiac tran s-
plantation as a valuable therapeutic method, improving both
the quantity and quality of life (1 ,2,7-13).
Age as a predictor of survival. Still, the age of the
recipient is considered to be a significant predictor of sur-
vival. The 1984 Report of the International Heart Trans-
plantation Registry (14) provided data on 1,076 patients
from 44 centers (1968 to 1984) and reported 6 year actuarial
survival rates (excluding 30 day mortality) of 28% for pa-
tient s more than 50 years of age , 34% for patients between
40 and 49 years of age and 51% for patients aged 30 to 39
year s. Patient age , the expertise of the center and the use
of cyclosporine were the most significant predictors of sur-
vival (14) . It is notable that in our experience the type of
immunosuppressive regimen employed does not affect sur-
vival (2).
Criteria for selection. In 1982, Pennock et al. (15 )
reported that only II % of 1,225 patients referred for eval-
uation were ultimately accepted for transplantation. Patients
older than 50 years were found to have a I year survival
rate of less than 40%. In our program , 29% of all patients
referred for evaluation have been accepted and 19% have
undergone transplantation. Forty referred patients have been
rejected mainly on the basis of advanced physiologic age
characterized by advanced chronologie age and evidence of
decreased function of secondary organ systems unrelated to
cardiac function. Of the referred patients over 50 years old ,
18% have been accepted and 11% have undergone trans-
plantation. In our selection process, age is not a contrain-
dication, yet it remains an important selection factor as
demonstrated by the lower percentage of patients accepted
and finally undergoing transplantation in this group (16) .
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Mortality and survival: role of age. It is interesting
that the mortality and complications, as well as survival,
do not differ from one age group to the other. The etiology
of end stage heart failure (ischemic versus others) did not
affect survival in our study. Aside from a greater proportion
of patients with ischemic heart disease in the older group,
the only significant difference between the two groups was
the number of patients under 50 years requiring pretrans-
plantation in-hospital care and inotropic therapy. This would
indicate that a more aggressive approach to end stage cardiac
disease was taken in younger patients.
Although the primary objective of cardiac transplantation
is patient survival, the quality of life for these patients is
equally important. We are pleased to observe that the suc-
cess of rehabilitation is excellent in both groups.
Conclusions. The results of cardiac transplantation are
not significantly different for those patients over and under
50 years of age. Thus, a rigidly defined age criterion for
potential cardiac recipients is currently unacceptable. A large
number of patients over 50 years of age with severe non-
surgical ischemic heart disease may be considered candi-
dates for cardiac transplantation if physiologic age is not
advanced by disease of other organ systems which may limit
survival. We believe that every potential recipient must be
evaluated individually in terms of the risk and benefit from
cardiac transplantation.
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